Table 2. Patient and Tumor Characteristics, Surgery, and Tumor Viability.
| Characteristic | No. (%) | ||
|---|---|---|---|
| RTOG 0630 (n = 79) | RTOG 9514 (n = 64) | Total (n = 143) | |
| Age, median (IQR) [range], y | 61 (51-71) [24-88] | 45.5 (36-53.5) [21-75] | 54 (42-65) [21-88] |
| Sex | |||
| Female | 37 (46.8) | 28 (43.8) | 65 (45.5) |
| Male | 42 (53.2) | 36 (56.3) | 78 (54.5) |
| Race | |||
| White, non-Hispanic | 68 (86.1) | 52 (81.3) | 120 (83.9) |
| All others | 11 (13.9) | 12 (18.8) | 23 (16.1) |
| Zubrod performance status | |||
| 0 | 61 (77.2) | 46 (71.9) | 107 (74.8) |
| 1 | 18 (22.8) | 18 (28.1) | 36 (25.2) |
| Disease location | |||
| Upper extremity | 11 (13.9) | 7 (10.9) | 18 (12.6) |
| Lower extremity | 62 (78.5) | 42 (65.6) | 104 (72.7) |
| Other (ie, hip, buttocks) | 6 (7.6) | 15 (23.4) | 21 (14.7) |
| Disease size (longest diameter, cm) | |||
| Median (IQR) [range], y | 10.5 (6.8-16) [3.5-30] | 15 (11.85-20) [8.2-55] | 12.5 (9.5-18.0) [3.5-55.0] |
| Histologic findings (local) | |||
| Epithelioid sarcoma | 0 | 1 (1.6) | 1 (0.7) |
| Extraskeletal myxoid chondrosarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Leiomyosarcoma | 9 (11.4) | 8 (12.5) | 17 (11.9) |
| Liposarcoma, NOS | 23 (29.1) | 14 (21.9) | 37 (25.9) |
| Liposarcoma, myxoid/round cell | 1 (1.3) | 0 | 1 (0.7) |
| Malignant peripheral nerve sheath tumor | 1 (1.3) | 1 (1.6) | 2 (1.4) |
| Myxofibrosarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Synovial sarcoma | 4 (5.1) | 3 (4.7) | 7 (4.9) |
| Unclassified sarcoma | 3 (3.8) | 6 (9.4) | 9 (6.3) |
| Undifferentiated pleomorphic sarcoma | 20 (25.3) | 16 (25.0) | 36 (25.2) |
| Undifferentiated spindle cell sarcoma | 16 (20.3) | 15 (23.4) | 31 (21.7) |
| Histologic findings (central review) | |||
| Epithelioid sarcoma | 0 | 1 (1.6) | 1 (0.7) |
| Extraskeletal myxoid chondrosarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Leiomyosarcoma | 8 (10.1) | 7 (10.9) | 15 (10.5) |
| Liposarcoma, myxoid/round cell | 13 (16.5) | 6 (9.4) | 19 (13.3) |
| Liposarcoma, pleomorphic | 1 (1.3) | 0 | 1 (0.7) |
| Liposarcoma, well-differentiated/dedifferentiated | 3 (3.8) | 0 | 3 (2.1) |
| Low-grade fibromyxoid sarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Malignant peripheral nerve sheath tumor | 1 (1.3) | 3 (4.7) | 4 (2.8) |
| Myxofibrosarcoma | 17 (21.5) | 3 (4.7) | 20 (14.0) |
| Rhabdomyosarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Sclerosing epithelioid fibrosarcoma | 1 (1.3) | 0 | 1 (0.7) |
| Synovial sarcoma | 4 (5.1) | 3 (4.7) | 7 (4.9) |
| Unclassified sarcoma | 3 (3.8) | 6 (9.4) | 9 (6.3) |
| Undifferentiated pleomorphic sarcoma | 18 (22.8) | 24 (37.5) | 42 (29.4) |
| Undifferentiated spindle cell sarcoma | 0 | 6 (9.4) | 6 (4.2) |
| Unknown | 7 (8.9) | 5 (7.8) | 12 (8.4) |
| Histologic grade (local) | |||
| G1 | 27 (34.2) | 0 | 27 (18.9) |
| G2 | 29 (36.7) | 13 (20.3) | 42 (29.4) |
| G3 | 20 (25.3) | 51 (79.7) | 71 (49.7) |
| Unknown | 3 (3.8) | 0 | 3 (2.1) |
| Histologic grade (central review) | |||
| G1 | 13 (16.5) | 0 | 13 (9.1) |
| G2 | 21 (26.6) | 12 (18.8) | 33 (23.1) |
| G3 | 38 (48.1) | 47 (73.4) | 85 (59.4) |
| Unknown | 7 (8.9) | 5 (7.8) | 12 (8.4) |
| Surgery | |||
| No | 5 (6.3) | 3 (4.7) | 8 (5.6) |
| Yes | 74 (93.7) | 61 (95.3) | 135 (94.4) |
| Amputation | |||
| No. | 74 | 61 | 135 |
| No | 73 (98.6) | 56 (91.8) | 129 (95.6) |
| Yes | 1 (1.4) | 5 (8.2) | 6 (4.4) |
| R status (local) | |||
| No. | 74 | 61 | 135 |
| R0 | 54 (73.0) | 56 (91.8) | 110 (81.5) |
| R1 | 18 (24.3) | 3 (4.9) | 21 (15.6) |
| R2 | 2 (2.7) | 0 | 2 (1.5) |
| Unknown | 0 | 2 (3.3) | 2 (1.5) |
| R status (central review) | |||
| No. | 74 | 61 | 135 |
| R0 | 56 (75.7) | 56 (91.8) | 112 (83.0) |
| R1 | 17 (23.0) | 3 (4.9) | 20 (14.8) |
| Unknown | 1 (1.4) | 2 (3.3) | 3 (2.2) |
| Tumor viability (central review) | |||
| No. | 74 | 61 | 135 |
| 0% | 14 (18.9) | 14 (23.0) | 28 (20.7) |
| 1%-24% | 22 (29.7) | 19 (31.1) | 41 (30.4) |
| 25%-50% | 10 (13.5) | 13 (21.3) | 23 (17.0) |
| 51%-75% | 6 (8.1) | 2 (3.3) | 8 (5.9) |
| 76%-100% | 20 (27.0) | 3 (4.9) | 23 (17.0) |
| Unknown | 2 (2.7) | 10 (16.4) | 12 (8.9) |
Abbreviations: NOS, not otherwise specified; RTOG, Radiation Therapy Oncology Group.